Pre-emption Defense: Pharma Must Show Record Of Interaction With FDA
Executive Summary
The Supreme Court's ruling in Wyeth v. Levine, which limits the circumstances in which companies can claim FDA-approved labeling pre-empts state product liability suits, is going to require companies to have a detailed dialogue with FDA
You may also be interested in...
Roche Gets Second Chance In Accutane Liability Suit; Pre-emption Still Possible
A New Jersey appeals court vacated a $2.6 million jury verdict against Roche and ordered a new trial to determine if its acne drug Accutane (isotretinoin) caused a plaintiff's inflammatory bowel disease
Pre-emption After Supreme Court Ruling May Depend On How FDA Weighs Risk
While the Supreme Court's landmark ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from product liability lawsuits, it will not trigger any sea change in litigation. Instead, the opinion seems likely to maintain the status quo and restrict the situations in which companies can claim they provided adequate warning of a drug's risks
Rx Injury Claims May Grow After Court Finds Brand Liable For Generic Problems
The pharmaceutical industry is reeling from a court ruling that found brand name manufacturers are liable for the warnings on generic versions of their products